Replies to post #9733 on Momenta Pharmaceuticals, Inc. (MNTA)

[jq1234]

Of the four compounds in late-stage development for RA profiled in the study, three-quarters of surveyed physicians were most interested in tofacitinib (Pfizer), the new JAK inhibitor, which the FDA will provide a decision about its approval on November 21st.

I can think of two others in late stage: AZN/RIGL's Fostamatinib, NVS's Secukinumab (IL-17). What is the other one? JNJ/GSK's Sirukumab (IL-6) entered ph3 recently, I don't think that counts.